123 related articles for article (PubMed ID: 32412074)
1. Using the SEER-Medicare Data to Assess Incident Chronic Myeloid Leukemia and Bladder Cancer Cases Missed by Cancer Registries.
Lam CJK; Warren JL; Nielsen M; Smith A; Boyd E; Barrett MJ; Mariotto AB
J Natl Cancer Inst Monogr; 2020 May; 2020(55):31-38. PubMed ID: 32412074
[TBL] [Abstract][Full Text] [Related]
2. Machine Learning Methods to Identify Missed Cases of Bladder Cancer in Population-Based Registries.
Noone AM; Lam CJK; Smith AB; Nielsen ME; Boyd E; Mariotto AB; Banerjee M
JCO Clin Cancer Inform; 2021 Jun; 5():641-653. PubMed ID: 34097440
[TBL] [Abstract][Full Text] [Related]
3. Underreporting of myeloid malignancies by United States cancer registries.
Craig BM; Rollison DE; List AF; Cogle CR
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):474-81. PubMed ID: 22237987
[TBL] [Abstract][Full Text] [Related]
4. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
Lang K; McGarry LJ; Huang H; Dorer D; Kaufman E; Knopf K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):275-285.e1. PubMed ID: 27013180
[TBL] [Abstract][Full Text] [Related]
5. Recent improvement in completeness of incidence data on acute myeloid leukemia in US cancer registries.
Polednak AP
J Registry Manag; 2014; 41(2):77-84. PubMed ID: 25153013
[TBL] [Abstract][Full Text] [Related]
6. Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.
Foulon S; Cony-Makhoul P; Guerci-Bresler A; Delord M; Solary E; Monnereau A; Bonastre J; Tubert-Bitter P
Cancer Med; 2019 Jun; 8(6):3296-3304. PubMed ID: 31038849
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of three algorithms to identify incident breast cancer in Medicare claims data.
Gold HT; Do HT
Health Serv Res; 2007 Oct; 42(5):2056-69. PubMed ID: 17850533
[TBL] [Abstract][Full Text] [Related]
8. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia.
Kenzik KM; Bhatia R; Williams GR; Bhatia S
Cancer; 2019 Aug; 125(15):2570-2578. PubMed ID: 30973642
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
10. An algorithm for the use of Medicare claims data to identify women with incident breast cancer.
Nattinger AB; Laud PW; Bajorunaite R; Sparapani RA; Freeman JL
Health Serv Res; 2004 Dec; 39(6 Pt 1):1733-49. PubMed ID: 15533184
[TBL] [Abstract][Full Text] [Related]
11. Identifying incident oral and pharyngeal cancer cases using Medicare claims.
Mahnken JD; Keighley JD; Girod DA; Chen X; Mayo MS
BMC Oral Health; 2013 Jan; 13():1. PubMed ID: 23280327
[TBL] [Abstract][Full Text] [Related]
12. [Descriptive epidemiology of myeloid leukemia].
Matsuo K; Ito H
Nihon Rinsho; 2009 Oct; 67(10):1847-51. PubMed ID: 19860178
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of coding algorithms to identify patients with incident lung cancer in United States healthcare claims data.
Beyrer J; Nelson DR; Sheffield KM; Huang YJ; Ellington T; Hincapie AL
Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1465-1479. PubMed ID: 33012044
[TBL] [Abstract][Full Text] [Related]
14. An approach to identifying incident breast cancer cases using Medicare claims data.
Freeman JL; Zhang D; Freeman DH; Goodwin JS
J Clin Epidemiol; 2000 Jun; 53(6):605-14. PubMed ID: 10880779
[TBL] [Abstract][Full Text] [Related]
15. Risk and survival of chronic myeloid leukemia after breast cancer: A population-based study.
Al-Husseini MJ; Mohamed HH; Saad AM; Gad MM; Atia M; Qaddoora U; Abushouk AI; El-Shinawi M
Curr Probl Cancer; 2019 Jun; 43(3):213-221. PubMed ID: 30195804
[TBL] [Abstract][Full Text] [Related]
16. Use of Medicare hospital and physician data to assess breast cancer incidence.
Warren JL; Feuer E; Potosky AL; Riley GF; Lynch CF
Med Care; 1999 May; 37(5):445-56. PubMed ID: 10335747
[TBL] [Abstract][Full Text] [Related]
17. Population-Based Testing and Treatment Characteristics for Chronic Myelogenous Leukemia.
Styles T; Wu M; Wilson R; Babcock F; Butterworth D; West DW; Richardson LC
J Registry Manag; 2016; 41(3):134-142. PubMed ID: 28121314
[TBL] [Abstract][Full Text] [Related]
18. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.
Brunner AM; Campigotto F; Sadrzadeh H; Drapkin BJ; Chen YB; Neuberg DS; Fathi AT
Cancer; 2013 Jul; 119(14):2620-9. PubMed ID: 23625575
[TBL] [Abstract][Full Text] [Related]
19. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
Shen C; Zhao B; Liu L; Shih YT
Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
[TBL] [Abstract][Full Text] [Related]
20. Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors.
Jamy O; Sarmad R; Costa L
Leuk Res; 2019 Jul; 82():1-6. PubMed ID: 31108340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
